Cardiólogo. PO-ICU #congenitalheart #interventionalcardilogy 🇲🇽 #structuralheart UMC Utrecht 🇳🇱 #cardiotwitter #radialfirst
Joined November 2018
- Tweets6.9K
- Following1.2K
- Followers2.3K
- Likes42K
Gian Manuel Jmz Rdz retweeted
1/3 @SCAI SHOCK⚡️🫀💥 Update 2026 Part 1 👉: 🔗 jscai.org/article/S2772-9303……
Gian Manuel Jmz Rdz retweeted
Coronary CT #CCTA takes center stage at #TCT2026!
A mobile CT scanner right in the Expo Hall, where attendees are undergoing coronary CT scans with real-time analysis using @HeartFlow technology.
Bringing the future of CT-guided PCI directly to TCT!
Gian Manuel Jmz Rdz retweeted
#TCT2026: PARADIGM met its primary endpoint, with favorable short-term outcomes. The results support this transcatheter device as a promising therapeutic option for paravalvular leak closure. 🔗 bit.ly/4BECH4U
#JACCINT @crfheart
Gian Manuel Jmz Rdz retweeted
🚨 PROGRESS results are out! TAVR is superior to clinical surveillance in selected patients with MODERATE aortic stenosis and at-risk features. A potential shift toward earlier intervention—with careful patient selection. #TCT2026 #TAVR @crfheart Great presentation from @PhilGenereuxMD 👏👏👏
nejm.org/doi/full/10.1056/NE…
Gian Manuel Jmz Rdz retweeted
🌴 Day 1 was one to remember. And we’re just getting started!
Thank you to everyone who made yesterday so special. We’re kicking off Day 2 of #TCT2026 with even more science, innovation, and unforgettable moments ahead.
✨ Here’s to another incredible day!
#CardioX #CardioTwitter #CardioEd #CardioResearch @BurkhoffMd @djc795 @ColletCarlos @georgedangas @jgranadacrf @mbmcentegart @Drroxmehran @sahilparikhmd @PopmaJeffrey @triciarawh @mirvatalasnag @TCTConference @TCTMD @m1chaella_alex @CathWhisperer @caldera_99 @SinaDaneshMD @CAESmedmd @Julio_Farjat @GolzarianH @JyotiJain_MD @Shikha_Cardio @DrBilal_khan @KrutarthKPandya @Shoaib9702 @IoannisSkalidis @Sticchi_Alex @ricosuruagy @ladyheart_md @AnaClaraVi75147 @anast_apost @padideh_daneii @MAnisHaider @Rushil_Vasudev
Gian Manuel Jmz Rdz retweeted
In STEMI patients with multivessel disease, reduced LVEF increases ischaemic risk — but the COMPLETE trial showed complete revascularisation reduces major CV events regardless of LVEF.
Read the full analysis by @DeniseTiong, et al.
eurointervention.pcronline.c…
@ShamirMehta, @Drroxmehran, @SVRaoMD
#CardioTwitter #InterventionalCardiology #PCI #MultivesselDisease #ClinicalResearch #EvidenceBasedMedicine
Gian Manuel Jmz Rdz retweeted
Fundamental concept of deformability of #calcifiednodules
doi: 10.4244/EIJ-D-25-00296
#Cardiology #interventionalcardiology #coronarycalcium @ziadalinyc @realarainmd @sbrugaletta @ShariqShamimMD @evandrofilhobr @mirvatalasnag @mmamas1973 @gbiondizoccai @FaustoHerediaDr @KAlaswadMD
Gian Manuel Jmz Rdz retweeted
🫀Finerenone vs spironolactone in heart failure with mildly reduced or preserved ejection fraction: a real-world study. see@ ow.ly/LcYk5100u04
@EJHFEiC @AmrAbdin10 @GiuseppeGalati_ @HanCardiomd @EJHFEiC @JanBiegus @ppponikowski #HFA_ESC @hvanspall @FudimMarat @gcfmd @MarcoMetra @GianluSava
#ESCHeartFailure
Gian Manuel Jmz Rdz retweeted
👉PCSK9 gene editing: One shot. Lifelong LDL-C lowering?
☝️ A new review explores the promise and challenges of CRISPR-based PCSK9 gene editing.
1️⃣ One-time treatment: A single infusion could provide lifelong reductions in PCSK9 expression and LDL-C.
2️⃣ Early human evidence: VERVE-102 and YOLT-101 have demonstrated substantial LDL-C reductions, reaching approximately 50% at selected doses.
3️⃣ The major advantage: Decades of LDL-C lowering without repeated dosing. A potentially transformative approach to cumulative cholesterol exposure.
4️⃣ Safety considerations: Early clinical results are encouraging. Larger studies and longer follow-up are needed to establish long-term safety and durability.
☝️ The next frontier: Can sustained LDL-C reduction from a single intervention translate into greater lifetime cardiovascular protection?
🔗🔓 doi.org/10.1007/s11883-026-0…
@amitvkhera
@society_eas
Gian Manuel Jmz Rdz retweeted
AngioVAC for left-sided intracardiac masses shows good effectiveness. Careful case selection, timely workup, and optimal embolic protection strategy are necessary. @PedroMDMSc @ShimamuraMD @DrMarvinEng @AhmadJabri8 @g_giustinoMD @vonBardelebenRS @engelpedro @Tiberio_Frisoli
Transcatheter vacuum-assisted extraction of left heart and aortic arch masses showed promising early effectiveness in this multicentre registry.
The observed rate of adverse events suggests the need for careful patient selection and improved procedural safety.
eurointervention.pcronline.c…
#InterventionalCardiology #StructuralHeart #TranscatheterInterventions
@fangjonathanx @PedroMDMSc @BillONeillMD @MichaelChiangCS @ArturoGiacaman @vonBardelebenRS
Gian Manuel Jmz Rdz retweeted
Tomizawa et al. found that super-resolution deep learning reconstruction (SR-DLR) improved CT-FFR performance, increasing AUC from 0.72 to 0.85 and diagnostic accuracy from 74% to 85% vs. normal-resolution DLR (NR-DLR).
doi.org/10.1016/j.jcct.2026.…
Gian Manuel Jmz Rdz retweeted
Cathlab echofusion in structural heart disease via @PCRonline pcronline.com/tiny/url/14200…
Gian Manuel Jmz Rdz retweeted
✂ Biopsy forceps... for pulmonary #thrombus removal?
When standard balloon angioplasty couldn't break the cycle of recurrent #CTO reocclusion, Nagayoshi et al. went off-label to mechanically remove an organized fibrotic "cap".
Read the case: asiaintervention.org/article…
Gian Manuel Jmz Rdz retweeted
Aspiración percutánea de vegetaciones en endocarditis derecha relacionada con catéteres #REC #Aheadofprint @pabl0salinas @vic_canadasg revespcardiol.org/es-aspirac…
Gian Manuel Jmz Rdz retweeted
Preemptive left stellate ganglion block was associated with a reduced incidence of postoperative atrial fibrillation within five postoperative days in patients undergoing CABG with cardiopulmonary bypass.
Read more in #JACCCEP 👉 bit.ly/4j7PmXf #CardioX
Gian Manuel Jmz Rdz retweeted
Missed a CardioTube session? Don't worry, we got you covered ❤️ catch up on all the latest #cardiology content! CRTTV.org has all the info 🫀
#CRTonline #interventionalcardiology #healthcare #technology #AI #nurses #doctors #tech #cathlab #medicine
Gian Manuel Jmz Rdz retweeted
When Is a Coronary Artery “Small”?
RCTs suggest DCBs are non-inferior to DES in small vessels. But where’s the cutoff?
The magic number for long-term stent patency is an MSA of 5.5 mm², corresponding to a vessel diameter of 2.6 mm. See the sizing chart below.
The question of the day: Is a ref. vessel dia. (RVD) of 2.75 mm the tipping point for choosing DES over DCB? 🤔
Gian Manuel Jmz Rdz retweeted
Thoughts on How to Achieve the Optimal MSA with PCI
The suggested cut-off of 2.75 mm in my previous post is to guide the choice between DCBs and DES.
It is NOT a suggested target MSA. The goal is to achieve at least 90% of the ref. MSA, as proposed by @SripalBangalore et al.
Additional thoughts on how to do this are in my reply.
Gian Manuel Jmz Rdz retweeted
Puntuación SYNTAX para la evaluación de la carga y complejidad de la enfermedad arterial coronaria: pasado, presente y futuro #REC #Aheadofprint @he1thj revespcardiol.org/es-puntuac…
